Cargando…
Upcoming Revolutionary Paths in Preclinical Modeling of Pancreatic Adenocarcinoma
To date, PDAC remains the cancer having the worst prognosis with mortality rates constantly on the rise. Efficient cures are still absent, despite all attempts to understand the aggressive physiopathology underlying this disease. A major stumbling block is the outdated preclinical modeling strategie...
Autores principales: | Swayden, Mirna, Soubeyran, Philippe, Iovanna, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6987422/ https://www.ncbi.nlm.nih.gov/pubmed/32038993 http://dx.doi.org/10.3389/fonc.2019.01443 |
Ejemplares similares
-
Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype
por: Swayden, Mirna, et al.
Publicado: (2018) -
Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma
por: Molejon, María Inés, et al.
Publicado: (2018) -
Tolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
por: Swayden, Mirna, et al.
Publicado: (2020) -
Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models
por: Hoare, Owen, et al.
Publicado: (2021) -
WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma
por: Hartman, Sarah J., et al.
Publicado: (2021)